Looks like Ricks got some explaining to do. House Oversight Committee to subpoena AbbVie for documents on Humira and Imbruvica pricing.
Make Rick testify under Oath.
“After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the Committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo
The Truth
“Although most of the drug companies we are examining have cooperated with the committee’s investigation, AbbVie’s noncompliance stands out as particularly egregious, which is why I am issuing this subpoena.”
The Lie
AbbVie said it has been cooperating with the committee since it received their initial letter in January 2019. “While we are surprised and disappointed the committee chose to take this action, we will continue to work in good faith with them on this important subject,” the drugmaker said in a statement.
After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the Committee's investigation," Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo
Make Rick testify under Oath.
For starters Rick needs to be asked the following:
How does executive pay/compensation matrix relate to Humira drug pricing?
Regarding he $15B stock buyback with Tax credit. What new jobs were created and what infrastructure (manufacturing plants, offices) in U.S.were constructed and where and at what cost?
Was there ever a discrepancy in the level of education attained by you on certain SEC FDA and other forms or filed documents NOT attributed to a clerical error?
What date were you briefed on the negative clinical data regarding Rova T?
What’s the status internally at Abbvie regarding California Commissioner Dave Jones complaint on behalf of the State of California against AbbVie Inc, alleging illegal kickbacks to healthcare providers to prescribe Humira.
What’s the status of FTC complaint against Abbvie for using strategies like pay for play to hinder or delay biosimilars from entering the market by Amgen and Samsung Bioepis?
European patients are already benefiting from significantly lower prices with biosimilar competition.Will Americans be without access to Humira biosimilars for almost 2 more years? — HR
